Download File - JOHN J. HADDAD, Ph.D.

Therapeutic and Prophylactic Cancer Vaccines 65
16. Hsueh EC, Essner R, Foshag LJ, et al. Active immunotherapy by reinduction with a
polyvalent allogeneic cell vaccine correlates with improved survival in recurrent
metastatic melanoma. Ann Surg Oncol 2002; 9(5):486–492.
17. DiFronzo LA, Gupta RK, Essner R, et al. Enhanced humoral immune response
correlates with improved disease-free and overall survival in American Joint Committee
on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
J Clin Oncol 2002; 20(15):3242–3248.
18. Ravindranath MH, Hsueh EC, Verma M, et al. Serum total ganglioside level correlates
with clinical course in melanoma patients after immunotherapy with therapeutic
cancer vaccine. J Immunother (1997) 2003; 26(3):277–285.
19. Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with
survival in melanoma patients with distant metastases receiving polyvalent melanoma
cell vaccine. J Clin Oncol 1998; 16(9):2913–2920.
20. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin
therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003; 13(6):401–407.
21. Morton DL, Hsueh EC, Essner R, et al. Prolonged survival of patients receiving
active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete
resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002; 236(4):
438–448; discussion 48–49.
22. Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. BioDrugs
2005; 19(4):247–260.
23. CancerVax Corporation. Available at: http://ir.cancervax.com/phoenix.zhtml?c=
147045&p=irol-newsArticle&t=Regular&id=763722&. Accessed 2005.
24. Harris JE, Ryan L, Hoover HC Jr., et al. Adjuvant active specific immunotherapy for
stage II and III colon cancer with an autologous tumor cell vaccine: Eastern
Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18(1):148–157.
25. Hanna MG Jr., Hoover HCJr., Vermorken JB, et al. Adjuvant active specific immunotherapy
of stage II and stage III colon cancer with an autologous tumor cell vaccine:
first randomized phase III trials show promise. Vaccine 2001; 19(17–19):2576–2582.
26. Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor
cell lysate vaccine: Melacine. Semin Cancer Biol 2003; 13(6):409–415.
27. Mitchell MS, Kan-Mitchell J, Kempf RA, et al. Active specific immunotherapy for
melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;
48(20):5883–5893.
28. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific
immunotherapy. Semin Oncol 1998; 25(6):623–635.
29. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected,
intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine:
overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol
2002; 20(8):2058–2066.
30. Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediatethickness,
node-negative melanoma with an allogeneic tumor vaccine: impact of HLA
class I antigen expression on outcome. J Clin Oncol 2002; 20(8):2067–2075.
31. Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to
active specific immunotherapy of melanoma. J Clin Oncol 1992; 10(7):1158–1164.
32. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Impact of cytokine administration
on the generation of antitumor reactivity in patients with metastatic melanoma
receiving a peptide vaccine. J Immunol 1999; 163(3):1690–1695.